Literature DB >> 34007811

Celiac Disease and Elevated Liver Enzymes: A Still Not Fully Defined Pathogenesis.

Linda Beenet1, Diego Tonesi2.   

Abstract

Entities:  

Year:  2021        PMID: 34007811      PMCID: PMC8111103          DOI: 10.14218/JCTH.2021.00074

Source DB:  PubMed          Journal:  J Clin Transl Hepatol        ISSN: 2225-0719


× No keyword cloud information.
Dear Editor, We read, with great interest, the comprehensive review by Villavicencio Kim J and Wu GY that systematically addressed the issue of liver enzyme elevation in celiac disease (CD) patients.1 The Authors reviewed, in detail, the most relevant studies reporting the frequency of liver enzyme elevation in CD patients and the possible causes, discussing the hypothesis that this elevation may be a clue to associated liver disease or an epiphenomenon, possibly secondary to the increased intestinal permeability that is known to characterize CD patients, especially at diagnosis, before starting a gluten-free diet.2 We would like to add some considerations that, in our opinion, could have implications in the pathogenesis of hepatic injury in CD. As known, it has been reported that CD is frequently associated with other extraintestinal autoimmune diseases or even with the mere presence of autoantibodies without concomitant autoimmune pathology.3–6 Among the autoimmune diseases potentially associated with CD, autoimmune hepatitis (AIH) is worthy of mention, as previously reported.1,3,7 Of considerable interest, it has been reported that celiac patients frequently have anti-filamentous actin IgA antibodies that have shown reliable and significant correlation with villous atrophy.8 These autoantibodies, although of IgG class, are also known to have very high specificity for AIH.7,9 This similarity between the two autoimmune diseases could be a clue that also supports possible immune-mediated pathogenesis of hypertransaminasemia in CD patients. Therefore, it would be relevant and worthy of study to analyze the presence of anti-actin antibodies in CD patients to verify whether these antibodies are markers of liver injury. Finally, it should not be overlooked, the very remarkable issue of the potential development of hepatic steatosis, which, as appropriately mentioned by the Authors, is not uncommon in CD patients with celiac disease after starting a gluten-free diet.10
  10 in total

1.  Anti-actin IgA antibodies in severe coeliac disease.

Authors:  A Granito; P Muratori; F Cassani; G Pappas; L Muratori; D Agostinelli; L Veronesi; R Bortolotti; N Petrolini; F B Bianchi; U Volta
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

2.  Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free diet.

Authors:  A Granito; D Zauli; P Muratori; L Muratori; A Grassi; R Bortolotti; N Petrolini; L Veronesi; P Gionchetti; F B Bianchi; U Volta
Journal:  Aliment Pharmacol Ther       Date:  2005-04-01       Impact factor: 8.171

3.  Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis.

Authors:  A Granito; L Muratori; P Muratori; G Pappas; M Guidi; F Cassani; U Volta; A Ferri; M Lenzi; F B Bianchi
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

4.  Anti tissue transglutaminase antibodies as predictors of silent coeliac disease in patients with hypertransaminasaemia of unknown origin.

Authors:  U Volta; A Granito; L De Franceschi; N Petrolini; F B Bianchi
Journal:  Dig Liver Dis       Date:  2001 Jun-Jul       Impact factor: 4.088

5.  Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free diet: beyond traditional metabolic factors.

Authors:  F Tovoli; G Negrini; R Farì; E Guidetti; C Faggiano; L Napoli; L Bolondi; A Granito
Journal:  Aliment Pharmacol Ther       Date:  2018-07-08       Impact factor: 8.171

6.  Coeliac disease in patients with autoimmune thyroiditis.

Authors:  U Volta; G Ravaglia; A Granito; P Forti; F Maioli; N Petrolini; M Zoli; F B Bianchi
Journal:  Digestion       Date:  2001       Impact factor: 3.216

7.  Anti-ganglioside antibodies in coeliac disease with neurological disorders.

Authors:  U Volta; R De Giorgio; A Granito; V Stanghellini; G Barbara; P Avoni; R Liguori; N Petrolini; E Fiorini; P Montagna; R Corinaldesi; F B Bianchi
Journal:  Dig Liver Dis       Date:  2006-02-07       Impact factor: 4.088

Review 8.  Diagnosis and therapy of autoimmune hepatitis.

Authors:  Alessandro Granito; Paolo Muratori; Silvia Ferri; Georgios Pappas; Chiara Quarneti; Marco Lenzi; Francesco B Bianchi; Luigi Muratori
Journal:  Mini Rev Med Chem       Date:  2009-06       Impact factor: 3.862

9.  Sera of patients with celiac disease and neurologic disorders evoke a mitochondrial-dependent apoptosis in vitro.

Authors:  Elisabetta Cervio; Umberto Volta; Manuela Verri; Federica Boschi; Ornella Pastoris; Alessandro Granito; Giovanni Barbara; Claudia Parisi; Cristina Felicani; Marcello Tonini; Roberto De Giorgio
Journal:  Gastroenterology       Date:  2007-05-03       Impact factor: 22.682

Review 10.  Celiac Disease and Elevated Liver Enzymes: A Review.

Authors:  Jaimy Villavicencio Kim; George Y Wu
Journal:  J Clin Transl Hepatol       Date:  2020-12-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.